James Ryan - BIONTECH Sr Counsel

B1NT34 Stock  BRL 40.80  1.36  3.45%   

Insider

James Ryan is Sr Counsel of BIONTECH SE DRN
Phone49 6131 9084 0
Webhttps://www.biontech.de

James Ryan Latest Insider Activity

Tracking and analyzing the buying and selling activities of James Ryan against BIONTECH stock is an integral part of due diligence when investing in BIONTECH. James Ryan insider activity provides valuable insight into whether BIONTECH is net buyers or sellers over its current business cycle. Note, BIONTECH insiders must abide by specific rules, including filing SEC forms every time they buy or sell BIONTECH'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

BIONTECH Management Efficiency

The company has return on total asset (ROA) of 0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BIONTECH's management efficiency ratios could be used to measure how well BIONTECH manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

EvaBritt AlleniusTelefonaktiebolaget LM Ericsson
N/A
Sandro TrentinRandon SA Implementos
N/A
Fredrik JejdlingTelefonaktiebolaget LM Ericsson
54
Scott DresserTelefonaktiebolaget LM Ericsson
56
Carl MellanderTelefonaktiebolaget LM Ericsson
59
Ellen WestAlphabet
N/A
Ricardo EscobozaRandon SA Implementos
N/A
MajBritt ArfertTelefonaktiebolaget LM Ericsson
60
Peter NyquistTelefonaktiebolaget LM Ericsson
58
Amie OTooleAlphabet
48
Esteban AngelettiRandon SA Implementos
N/A
Sergio CarvalhoRandon SA Implementos
N/A
Veridiana SonegoRandon SA Implementos
N/A
Philipp SchindlerAlphabet
52
Daniel ElyRandon SA Implementos
N/A
Anderson PontaltiRandon SA Implementos
N/A
Paulo PrignolatoRandon SA Implementos
N/A
Jessica CanteleFras le SA
N/A
Fiona CicconiAlphabet
57
MSc MBATelefonaktiebolaget LM Ericsson
60
Prabhakar RaghavanAlphabet
62
BIONTECH SE DRN (B1NT34) is traded on Sao Paulo Exchange in Brazil and employs 4,000 people.

Management Performance

BIONTECH SE DRN Leadership Team

Elected by the shareholders, the BIONTECH's board of directors comprises two types of representatives: BIONTECH inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIONTECH. The board's role is to monitor BIONTECH's management team and ensure that shareholders' interests are well served. BIONTECH's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIONTECH's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jens Holstein, CFO Board
Sylke Maas, VP Strategy
James Ryan, Sr Counsel
Michael Boehler, MD Communications
Ryan Richardson, MD Officer
Sierk Poetting, COO MD
Pr MD, CoFounder Board
Ozlem MD, Chief CoFounder
Sean Marett, Chief Officer

BIONTECH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIONTECH a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BIONTECH Stock

BIONTECH financial ratios help investors to determine whether BIONTECH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIONTECH with respect to the benefits of owning BIONTECH security.